Skip to main
ATXS
ATXS logo

Astria Therapeutics (ATXS) Stock Forecast & Price Target

Astria Therapeutics (ATXS) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 50%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Astria Therapeutics Inc. is positioned positively due to the promising preclinical results of its product candidates, particularly STAR-0310, which demonstrated favorable tolerability without adverse events typically associated with treatment, suggesting potential for enhanced efficacy compared to existing therapies. The merger with BioCryst has been viewed as a validation of Astria's strategy, expected to yield synergistic benefits that can enhance operating profits starting from the first full year following the launch of navenibart. Furthermore, Astria is anticipated to capitalize on a large commercial market opportunity, with expectations of significant news flow that could facilitate pipeline expansion and strategic growth initiatives.

Bears say

The financial outlook for Astria Therapeutics Inc is negatively impacted by several critical factors, notably the risk of failed or inconclusive clinical trials for its product candidates, STAR-0215 and STAR-0310. Additionally, the company's ability to secure adequate funding to support the progression of its drug development is uncertain, posing a significant threat to its operational continuity. Furthermore, risks regarding the completion of any acquisition and potential competition from other bidders may further complicate the company's valuation and hinder the achievement of clinical milestones necessary for financial stability.

Astria Therapeutics (ATXS) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 50% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astria Therapeutics (ATXS) Forecast

Analysts have given Astria Therapeutics (ATXS) a Buy based on their latest research and market trends.

According to 6 analysts, Astria Therapeutics (ATXS) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astria Therapeutics (ATXS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.